-
Mashup Score: 60
The Investor Relations website contains information about Syndax Pharmaceuticals, Inc.’s business for stockholders, potential investors, and financial analysts.
Source: ir.syndax.comCategories: General Medicine News, Hem/OncsTweet
The Investor Relations website contains information about Syndax Pharmaceuticals, Inc.’s business for stockholders, potential investors, and financial analysts.
It was an honor to present interim results of Aza/Ven + Revumenib in newly Dx older AML pts with NPM1 mut or KMT2Ar on behalf of my co-authors & @LLSusa @EHA_Hematology. Regimen is highly active & hopeful this can make a huge impact in #AML @UNC_Lineberger https://t.co/G7FXFO2eXf https://t.co/HfaAOThdY2